Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study
Dorairaj Prabhakaran, Kavita Singh, Dimple Kondal, Lana Raspail, Bishav Mohan, Toru Kato, Nizal Sarrafzadegan, Shamim Hayder Talukder, Shahin Akter, Mohammad Robed Amin, Fastone Goma, Juan Gomez-Mesa, Ntobeko Ntusi, Francisca Inofomoh, Surender Deora, Evgenii Philippov, Alla Svarovskaya, Alexandra Konradi, Aurelio Puentes, Okechukwu S Ogah, Bojan Stanetic, Aurora Issa, Friedrich Thienemann, Dafsah Juzar, Ezequiel Zaidel, Sana Sheikh, Dike Ojji, Carolyn S P Lam, Junbo Ge, Amitava Banerjee, L Kristin Newby, Antonio Luiz P Ribeiro, Samuel Gidding, Fausto Pinto, Pablo Perel, Karen Sliwa, WHF COVID-19 Study Collaborators, Dorairaj Prabhakaran, Kavita Singh, Dimple Kondal, Lana Raspail, Bishav Mohan, Toru Kato, Nizal Sarrafzadegan, Shamim Hayder Talukder, Shahin Akter, Mohammad Robed Amin, Fastone Goma, Juan Gomez-Mesa, Ntobeko Ntusi, Francisca Inofomoh, Surender Deora, Evgenii Philippov, Alla Svarovskaya, Alexandra Konradi, Aurelio Puentes, Okechukwu S Ogah, Bojan Stanetic, Aurora Issa, Friedrich Thienemann, Dafsah Juzar, Ezequiel Zaidel, Sana Sheikh, Dike Ojji, Carolyn S P Lam, Junbo Ge, Amitava Banerjee, L Kristin Newby, Antonio Luiz P Ribeiro, Samuel Gidding, Fausto Pinto, Pablo Perel, Karen Sliwa, WHF COVID-19 Study Collaborators
Abstract
Background and aims: Limited data exist on the cardiovascular manifestations and risk factors in people hospitalized with COVID-19 from low- and middle-income countries. This study aims to describe cardiovascular risk factors, clinical manifestations, and outcomes among patients hospitalized with COVID-19 in low, lower-middle, upper-middle- and high-income countries (LIC, LMIC, UMIC, HIC).
Methods: Through a prospective cohort study, data on demographics and pre-existing conditions at hospital admission, clinical outcomes at hospital discharge (death, major adverse cardiovascular events (MACE), renal failure, neurological events, and pulmonary outcomes), 30-day vital status, and re-hospitalization were collected. Descriptive analyses and multivariable log-binomial regression models, adjusted for age, sex, ethnicity/income groups, and clinical characteristics, were performed.
Results: Forty hospitals from 23 countries recruited 5,313 patients with COVID-19 (LIC = 7.1%, LMIC = 47.5%, UMIC = 19.6%, HIC = 25.7%). Mean age was 57.0 (±16.1) years, male 59.4%, pre-existing conditions included: hypertension 47.3%, diabetes 32.0%, coronary heart disease 10.9%, and heart failure 5.5%. The most frequently reported cardiovascular discharge diagnoses were cardiac arrest (5.5%), acute heart failure (3.8%), and myocardial infarction (1.6%). The rate of in-hospital deaths was 12.9% (N = 683), and post-discharge 30 days deaths was 2.6% (N = 118) (overall death rate 15.1%). The most common causes of death were respiratory failure (39.3%) and sudden cardiac death (20.0%). The predictors of overall mortality included older age (≥60 years), male sex, pre-existing coronary heart disease, renal disease, diabetes, ICU admission, oxygen therapy, and higher respiratory rates (p < 0.001 for each). Compared to Caucasians, Asians, Blacks, and Hispanics had almost 2-4 times higher risk of death. Further, patients from LIC, LMIC, UMIC versus. HIC had 2-3 times increased risk of death.
Conclusions: The LIC, LMIC, and UMIC's have sparse data on COVID-19. We provide robust evidence on COVID-19 outcomes in these countries. This study can help guide future health care planning for the pandemic globally.
Keywords: COVID-19; cardiovascular disease; mortality.
Conflict of interest statement
The authors have no competing interests to declare.
Copyright: © 2022 The Author(s).
Figures
References
- Thienemann F, Pinto F, Grobbee DE, et al. World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries. Glob Heart. 2020; 15(1): 31. [published Online first: 4 June 2020]. DOI: 10.5334/gh.778
- Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in Low- and Middle-Income Countries. JAMA. 2020; 323(16): 1549–50. [published Online first: 17 March 2020]. DOI: 10.1001/jama.2020.4169
- Angrup A, Kanaujia R, Ray P, et al. Healthcare facilities in low- and middle-income countries affected by COVID-19: Time to upgrade basic infection control and prevention practices. Indian J Med Microbiol. 2020; 38(2): 139–43. [published Online first: 05 September 2020]. DOI: 10.4103/ijmm.IJMM_20_125
- Grasselli G, Greco M, Zanella A, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020; 180(10): 1345–55. [published Online first: 16 July 2020]. DOI: 10.1001/jamainternmed.2020.3539
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8): 782–93. [published Online first: 11 July 2020]. DOI: 10.1001/jama.2020.12839
- O’Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021; 590(7844): 140–45. [published Online first: 3 November 2020]. DOI: 10.1038/s41586-020-2918-0
- Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. The Lancet Infectious Diseases. 2020; 20(6): 669–77. DOI: 10.1016/S1473-3099(20)30243-7
- Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021; 97(1147): 312–20. [published Online first: 27 September 2020]. DOI: 10.1136/postgradmedj-2020-138577
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020; 8(5): 475–81. DOI: 10.1016/S2213-2600(20)30079-5
- Xiong T-Y, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J. 2020; 41(19): 1798–800. DOI: 10.1093/eurheartj/ehaa231
- Alharthy A, Aletreby W, Faqihi F, et al. Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study. J Epidemiol Glob Health. 2021; 11(1): 98–104. [published Online first: 24 October 2020]. DOI: 10.2991/jegh.k.200928.001
- Adu-Amankwaah J, Mprah R, Adekunle AO, et al.The cardiovascular aspect of COVID-19. Ann Med. 2021; 53(1): 227–36. [published Online first: 22 December 2020]. DOI: 10.1080/07853890.2020.1861644
- Sliwa K, Singh K, Raspail L, et al. The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. Glob Heart. 2021; 16(1): 22. [published Online first: 28 May 2021]. DOI: 10.5334/gh.950
- Bank W. Poverty and Shared Prosperity 2020: Reversals of Fortune. 2020.
- Bukhman G, Mocumbi AO, Atun R, et al. The Lancet NCDI Poverty Commission: Bridging a gap in universal health coverage for the poorest billion. The Lancet. 2020; 396(10256): 991–1044. DOI: 10.1016/S0140-6736(20)31907-3
- World Bank county classification by income. (Accessed 04 January 2022). .
- Alkmim MB, Silva CBG, Figueira RM, et al. Brazilian National Service of Telediagnosis in Electrocardiography. Stud Health Technol Inform. 2019; 264: 1635–36. [published Online first: 24 August 2019]. DOI: 10.3233/shti190571
- Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42(2): 377–81. [published Online first: 22 October 2008]. DOI: 10.1016/j.jbi.2008.08.010
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95: 103208. [published Online first: 13 May 2019]. DOI: 10.1016/j.jbi.2019.103208
- Karp I. Re: ‘Estimating the relative risk in cohort studies and clinical trials of common outcomes’. Am J Epidemiol. 2014; 179(8): 1034–5. [published Online first: 21 February 2014]. DOI: 10.1093/aje/kwt435
- McNutt LA, Wu C, Xue X, et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157(10): 940–3. [published Online first: 15 May 2003]. DOI: 10.1093/aje/kwg074
- Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159(7): 702–6. [published Online first: 23 March2004]. DOI: 10.1093/aje/kwh090
- Dai CL, Kornilov SA, Roper RT, et al. Characteristics and Factors Associated with COVID-19 Infection, Hospitalization, and Mortality Across Race and Ethnicity. Clin Infect Dis; 2021. [published Online first: 21 February 2021]. DOI: 10.1093/cid/ciab154
- Acosta AM, Garg S, Pham H, et al. Racial and Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021. JAMA Netw Open. 2021; 4(10): e2130479. [published Online first: 22 October 2021]. DOI: 10.1001/jamanetworkopen.2021.30479
- Qureshi AI, Baskett WI, Huang W, et al. Effect of Race and Ethnicity on In-Hospital Mortality in Patients with COVID-19. Ethn Dis. 2021; 31(3): 389–98. [published Online first: 24 July 2021]. DOI: 10.18865/ed.31.3.389
- Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J. 2020; 41(19): 1798–800. [published Online first: 19 March 2020]. DOI: 10.1093/eurheartj/ehaa231
- Behrouzi B, Araujo Campoverde MV, Liang K, et al. Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 76(15): 1777–94. [published Online first: 10 October 2020]. DOI: 10.1016/j.jacc.2020.08.028
- Yedlapati SH, Khan SU, Talluri S, et al. Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2021; 10(6): e019636. [published Online first: 16 March 2021]. DOI: 10.1161/JAHA.120.019636
- Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-analysis. JAMA. 2013; 310(16): 1711–20. [published Online first: 24 October 2013]. DOI: 10.1001/jama.2013.279206
- Verma S, Saksena S, Sadri-Ardekani H. ACE2 receptor expression in testes: Implications in coronavirus disease 2019 pathogenesisdagger. Biol Reprod. 2020; 103(3): 449–51. [published Online first: 20 May 2020]. DOI: 10.1093/biolre/ioaa080
- Al-Benna S. Angiotensin-converting enzyme 2 gene expression in human male urological tissues: implications for pathogenesis and virus transmission pathways. Afr J Urol. 2021; 27(1): 89. [published Online first: 8 July 2021]. DOI: 10.1186/s12301-021-00192-4
- Prabhakaran D, Chandrasekaran AM, Singh K, et al. Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction: A Randomized Trial. J Am Coll Cardiol. 2020; 75(13): 1551–61. [published Online first: 4 April 2020]. DOI: 10.1016/j.jacc.2020.01.050
- Dhakal BP, Sweitzer NK, Indik JH, et al. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung Circ. 2020; 29(7): 973–87. [published Online first: 1 July 2020]. DOI: 10.1016/j.hlc.2020.05.101
- Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020; 17(9): 543–58. [published Online first: 22 July 2020]. DOI: 10.1038/s41569-020-0413-9
- Ma L, Song K, Huang Y. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. J Cardiothorac Vasc Anesth. 2021; 35(6): 1860–65. [published Online first: 27 May 2020]. DOI: 10.1053/j.jvca.2020.04.041
- Chang WT, Toh HS, Liao CT, et al. Cardiac Involvement of COVID-19: A Comprehensive Review. Am J Med Sci. 2021; 361(1): 14–22. [published Online first: 15 November 2020]. DOI: 10.1016/j.amjms.2020.10.002
- Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020; 5(7): 802–10. DOI: 10.1001/jamacardio.2020.0950
- Pareek M, Singh A, Vadlamani L, et al. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). Am J Cardiol. 2021; 146: 99–106. [published Online first: 5 February 2021]. DOI: 10.1016/j.amjcard.2021.01.029
- Mehraeen E, Karimi A, Barzegary A, et al. Predictors of mortality in patients with COVID-19-a systematic review. Eur J Integr Med. 2020; 40: 101226. [published Online first: 27 October 2020]. DOI: 10.1016/j.eujim.2020.101226
- Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020; 369: m1328. [published Online first: 9 April2020]. DOI: 10.1136/bmj.m1328
- Zhang JJY, Lee KS, Ang LW, et al. Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. Clin Infect Dis. 2020; 71(16): 2199–206. [published Online first: 15 May 2020]. DOI: 10.1093/cid/ciaa576
- Mesas AE, Cavero-Redondo I, Alvarez-Bueno C, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020; 15(11): e0241742. [published Online first: 4 November 2020]. DOI: 10.1371/journal.pone.0241742
- Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020; 130(4): 304–09. [published Online first: 2 April 2020]. DOI: 10.20452/pamw.15272
- Mubarik S, Liu X, Eshak ES, et al. The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. Front Med (Lausanne). 2021; 8: 623608. [published Online first: 1 June 2021]. DOI: 10.3389/fmed.2021.623608
- Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm Sin B. 2021; 11(1): 1–12. [published Online first: 20 October 2020]. DOI: 10.1016/j.apsb.2020.10.006
- Wu J, Deng W, Li S, et al. Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci. 2021; 78(2): 531–44. [published Online first: 12 August 2020]. DOI: 10.1007/s00018-020-03611-x
Source: PubMed